Metformin suppresses cancer initiation and progression in genetic mouse models of pancreatic cancer

BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer-associated mortality worldwide with an overall five-year survival rate less than 7%. Accumulating evidence has revealed the cancer preventive and therapeutic effects of metformin, one of the most widely prescri...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Mol Cancer
Autors principals: Chen, Ke, Qian, Weikun, Jiang, Zhengdong, Cheng, Liang, Li, Jie, Sun, Liankang, Zhou, Cancan, Gao, Luping, Lei, Meng, Yan, Bin, Cao, Junyu, Duan, Wanxing, Ma, Qingyong
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2017
Matèries:
Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5525317/
https://ncbi.nlm.nih.gov/pubmed/28738823
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12943-017-0701-0
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars